About Cyclic AMP-dependent transcription factor ATF-4
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) is a protein
from Homo sapiens identified by UniProt accession
P18848, 351 residues long.
MolForge cross-references it against 0 known binders and
523 disease associations.
Target properties
| Protein name | Cyclic AMP-dependent transcription factor ATF-4 |
| UniProt accession | P18848 |
| Gene | ATF4 |
| Organism | Homo sapiens |
| Length | 351 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (523)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.55
- lysosomal storage disease · score 0.37
- mean corpuscular volume · score 0.32
- mean corpuscular hemoglobin concentration · score 0.31
- mean corpuscular hemoglobin · score 0.28
- Immature Reticulocyte Fraction Measurement · score 0.25
- reticulocyte measurement · score 0.22
- neurotic disorder · score 0.20
- protein measurement · score 0.15
- neoplasm · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P18848-F1 | alphafold | PREDICTED | 62.00 | — |
Amino-acid sequence (351 residues)
MTEMSFLSSE VLVGDLMSPF DQSGLGAEES LGLLDDYLEV AKHFKPHGFS SDKAKAGSSE WLAVDGLVSP SNNSKEDAFS GTDWMLEKMD LKEFDLDALL GIDDLETMPD DLLTTLDDTC DLFAPLVQET NKQPPQTVNP IGHLPESLTK PDQVAPFTFL QPLPLSPGVL SSTPDHSFSL ELGSEVDITE GDRKPDYTAY VAMIPQCIKE EDTPSDNDSG ICMSPESYLG SPQHSPSTRG SPNRSLPSPG VLCGSARPKP YDPPGEKMVA AKVKGEKLDK KLKKMEQNKT AATRYRQKKR AEQEALTGEC KELEKKNEAL KERADSLAKE IQYLKDLIEE VRKARGKKRV P
Explore Cyclic AMP-dependent transcription factor ATF-4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets